108 related articles for article (PubMed ID: 30605956)
81. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
[TBL] [Abstract][Full Text] [Related]
82. Tuberous sclerosis with two unusual findings: cutaneous rhabdomyoma and chronic myelogenous leukaemia.
Bardawil T; El Jamal L; Abbas O; Kurban M
Clin Exp Dermatol; 2020 Aug; 45(6):799-801. PubMed ID: 32097503
[No Abstract] [Full Text] [Related]
83. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
[TBL] [Abstract][Full Text] [Related]
84. Mammalian target of rapamycin inhibitors in a patient with polycystic kidney disease-1-tuberous sclerosis-2 contiguous gene syndrome.
Anandh U; Chandrasekar G; Agarwal V
Saudi J Kidney Dis Transpl; 2018; 29(6):1475-1479. PubMed ID: 30588981
[TBL] [Abstract][Full Text] [Related]
85. Malignancy of renal angiomyolipoma from tuberous sclerosis complex with TSC2 mutation.
Huang YJ; Jiang ZP; Chen YP; Wu JQ; Huang JL; Chen YQ; Liang MJ
Chin Med J (Engl); 2019 Jan; 132(1):103-105. PubMed ID: 30628968
[No Abstract] [Full Text] [Related]
86. [The 467th case: proteinuria, periungual fibromas, and facial steatadenomas].
Chen G; Dong QR; Li MX; Li XM
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):74-77. PubMed ID: 30605956
[TBL] [Abstract][Full Text] [Related]
87. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
[TBL] [Abstract][Full Text] [Related]
88. Tuberous sclerosis complex: tumors and tumorigenesis.
Borkowska J; Schwartz RA; Kotulska K; Jozwiak S
Int J Dermatol; 2011 Jan; 50(1):13-20. PubMed ID: 21182496
[TBL] [Abstract][Full Text] [Related]
89. [Terminal kidney insufficiency in tuberous sclerosis].
Krieter DH; Müller GA
Dtsch Med Wochenschr; 1995 May; 120(20):718-22. PubMed ID: 7758411
[TBL] [Abstract][Full Text] [Related]
90. [Tuberous sclerosis].
Metsähonkala L; Valanne L; Anttonen AK
Duodecim; 2013; 129(17):1779-87. PubMed ID: 24159711
[TBL] [Abstract][Full Text] [Related]
91. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
92. Tuberous sclerosis complex: advances in diagnosis, genetics, and management.
Schwartz RA; Fernández G; Kotulska K; Jóźwiak S
J Am Acad Dermatol; 2007 Aug; 57(2):189-202. PubMed ID: 17637444
[TBL] [Abstract][Full Text] [Related]
93. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
94. Bilateral renal angiomyolipomatosis in tuberous sclerosis presenting with chronic renal failure: case report and review of the literature.
Kalra OP; Verma PP; Kochhar S; Jha V; Sakhuja V
Nephron; 1994; 68(2):256-8. PubMed ID: 7830866
[TBL] [Abstract][Full Text] [Related]
95. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
Coombs EJ
J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
[TBL] [Abstract][Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
